Public Employees Retirement Association of Colorado Sells 230 Shares of Insulet Co. (NASDAQ:PODD)

Public Employees Retirement Association of Colorado cut its stake in shares of Insulet Co. (NASDAQ:PODD) by 3.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,183 shares of the medical instruments supplier’s stock after selling 230 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Insulet were worth $1,450,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in shares of Insulet in the second quarter worth approximately $32,000. Sunbelt Securities Inc. bought a new stake in shares of Insulet in the 1st quarter valued at $29,000. UMB Bank n.a. boosted its stake in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. Jones Financial Companies Lllp acquired a new stake in shares of Insulet during the fourth quarter worth $40,000. Finally, CVA Family Office LLC lifted its holdings in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $234.00 price target on shares of Insulet in a report on Tuesday, July 23rd. BTIG Research decreased their target price on Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Barclays boosted their price target on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. UBS Group increased their price target on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, Redburn Atlantic initiated coverage on shares of Insulet in a research note on Thursday, May 30th. They issued a “buy” rating and a $235.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $229.21.

Insulet Stock Performance

Shares of Insulet stock opened at $239.01 on Wednesday. The company has a market cap of $16.74 billion, a PE ratio of 72.43, a price-to-earnings-growth ratio of 4.38 and a beta of 1.21. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet Co. has a 52 week low of $125.82 and a 52 week high of $243.98. The business has a 50 day moving average price of $204.43 and a 200-day moving average price of $189.34.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The company had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. During the same quarter last year, the business posted $0.38 earnings per share. Insulet’s revenue was up 23.2% on a year-over-year basis. Equities analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.